Wadenswil, Switzerland, March 1, 2019 - Creoptix AG, a Switzerland-based company focused on next generation bioanalytical instruments, today proudly announced Gareth Jones joining the senior management team as VP Global Sales Operations

“We are very happy to have Gareth joining our company. He brings in vast experience in building up sales teams and establishing innovative new technologies in the analytical instrument business,“ said Matyas Vegh, CEO of Creoptix. “This is exactly what we need now after having generated first momentum with our technology.”

Gareth Jones joins Creoptix coming from TTP Labtech where he held the position of Director of European Sales & Support. Gareth brings over 25 years of commercial experience in the Life science sector, working with several small and large brands like Bio-Rad, Applied Biosystems, Cyntellect and GE Healthcare where he held sales operations or market development positions on European or global level.
“I am truly excited to be joining such a dynamic and innovative company like Creoptix. I believe Creoptix has the technology and capability to transform the way label free analysis is utilised within the drug discovery workflow and provide functionality that has, up until now, not been available with incumbent technology to date.

About Creoptix
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and offices near Boston, USA. Creoptix focuses on next generation bioanalytical instruments for drug discovery and development as well as academic research. Based on its proprietary sensor and microfluidics technology, their Creoptix WAVE systems provide exceptionally high sensitivity and resolution in characterizing real-time interactions between small molecules, peptides, proteins and other molecules and in even crude samples like undiluted serum or plasma.

Press Release

Our biomolecular interactions workshop is taking place on November 9th. Join us for an introduction to GCI, hands-on time with our WAVEdelta and refreshments at the MassBio Collaboration Room, 300 Technology Square in Cambridge, MA.
 
Click here to register or contact Kevin Jackvony This email address is being protected from spambots. You need JavaScript enabled to view it.

To further strengthen our sales efforts in the US, we proudly welcome Kevin M. Jackvony as National Sales Manager – US & Canada. From his work with several brands like Rainin, GE Healthcare and, most recently, Qiagen. Kevin brings a wealth of capital equipment sales experience to Creoptix. Kevin is based in the Boston area. We hope you will soon have the opportunity to meet him in person.

Creoptix will be participating in the Festival of Biologics 2018, taking place between October 29^th-31^st in Basel, Switzerland. Free passes are available.

Catch the WAVE of the future in kinetics! Tells us about your wishes in label-free sensing and kinetics.
Link: www.creoptix.com/icatchthenextwave

Wadenswil, Switzerland, September 5, 2018 - Creoptix AG, a Switzerland-based company focused on next generation bioanalytical instruments, today announced it secured new investment in the company from Waters Corporation (NYSE: WAT). Additionally, Geoff Gerhardt, Ph.D.,
Sr. Director, Corporate Development at Waters will join Creoptix board of directors effective immediately.
PRESS RELEASE

Dr. Ulrich Hohmann, from Prof. Michael Hothorn’s group at the University of Geneva, will be talking about LRR-RK signalling during the Peptides and Receptors in Plant Development session that Creoptix is sponsoring on September 6^th.

http://www.6th-workshop-plant-peptides-and-receptors.cbgp.upm.es/

Dr. Michael Hennig, CEO of leadXpro, will talk about the company’s experience with the Creoptix WAVE system when measuring ligand binding and kinetics to support drug design on September 27^th at 3:55 pm.

The binding kinetics of several approved drugs Danusertib, among others to Aurora A Kinase were recently studied by the lab of Dr. Dorothee Kern at Brandeis University. The group published the results in the open access journal e-Life. (Danusertib, among others)

The Creoptix WAVE system helps reveal new insights in brassinosteroid signalling. The results, obtained by Prof. Michael Hothorn’s group at the University of Geneva, were recently published in Nature Plants.

Prof. Michael Hothorn’s group at the University of Geneva studied the activation of plant membrane receptor kinases with the Creoptix WAVE system. Read all about it in this open access PNAS paper.

Creoptix announces entering UK market with Mologic as first customer and providing new research avenues for Mologic’s Centre for Advanced Rapid Diagnostics (“CARD”) Press Release

We are hiring sales representatives for Europe and the US.

Please check out our Career site.

In order to strengthen our sales efforts and our customer support, Creoptix is hiring a Field Application Scientist for the US Territory. Please find the profile here: Field Application Scientist – US Territory

In order to strengthen our sales efforts, Creoptix is seeking a Sales Manager North America. Please find the profile here: Sales Manager North America

Small Molecules can't hide anymore...not even behind large drug targets! Thanks to Novartis for providing the material, our new TechNote shows how Creoptix WAVE pushes the limits regarding sensitivity: Kinetics of a 300Da small molecule with a 110 kDa drug target at Rmax below 1 pg/mm2! Tech Note

Creoptix proudly announces three new Tech Notes demonstrating the benefits of the Creoptix™ WAVE system for molecular interaction analysis:

Fast Off-Rates: Based on very fast injection processes, the Creoptix™ WAVE enables reliable analysis of off-rates of 5 per second! This now allows for off-rate screening and ranking of weak binders such as fragments in a very early discovery process.

Kinetics at High Serum: The innovative disposable microfluidics of the Creoptix™ WAVE provides very high robustness against complex matrices and does not clog at even 100% untreated blood serum. This allows kinetic analysis at much higher serum concentrations than ever before.

Avoiding Mass Transport: Kinetic data quality is significantly impaired by mass transport due to the high immobilization levels required. Thanks to the exceptionally high sensitivity of the Creoptix™ WAVE, reliable kinetics below 1 pg/mm2 are possible and immobilization levels can be markedly reduced. This not only reduces sample consumption but also mass transport limitation.

Creoptix is looking forward to meeting Merck's scientists at the upcoming Merck Technology Symposium taking place on June 2-3, 2015 in Somerset NJ

Creoptix to exhibit at the Drug Discovery Chemistry 2015 in San Diego CA, April 21-23, 2015

Creoptix to exhibit at the Fragments 2015 in Cambridge UK, March 22-24, 2015

Creoptix to exhibit at the Label-Free Technologies Conference in Cambridge MA, March 12-14, 2015

Creoptix proudly announces Dr. Walter Huber as keynote speaker on workshop on March 11 at Swissnex Boston:

Swiss Excellence in Drug Discovery featuring Dr. Walter Huber: "Label-Free Technologies - Overview, Experiences & Perspectives"

Click here for further information and free registration!

Creoptix selected to present at the Late Night with LRIG at the upcoming SLAS2015 in Washington DC. We look forward to seeing you soon in Washinton!

Creoptix to exhibit at the Future Expo during the Eureka Innovation Event and the Swiss Innovation Forum in Basel, Switzerland on November 19 & 20 (Future Expo exhibitor list: DE / ENG)

Creoptix to exhibit at the 10th Annual European Antibody Congress in Geneva, Switzerland on November 10-12, 2014

Creoptix to support the Fragment-based Lead Discovery Conference 2014 in Basel, Switzerland on September 21-24, 2014

Creoptix AG announces carbonic anhydrase data highlighting the exceptional high resolution of the Creoptix™ WAVE system.

Creoptix AG announces the launch of its WAVE system.

We have moved into new facilities, you can now reach us at Einsiedlerstrasse 34, CH-8820 Wädenswil.

Creoptix to support the 15th Annual Drug Discovery Summit in Geneva (press release).